Colton H, Barratt N, Temperton N, Hornsby H, Angyal A, Grouneva I
Br J Haematol. 2024; 205(6):2206-2218.
PMID: 39551718
PMC: 11637739.
DOI: 10.1111/bjh.19874.
Serna A, Navarro V, Iacoboni G, Lopez L, Sancho J, Gonzalez-Barca E
Haematologica. 2024; 110(1):173-178.
PMID: 38988269
PMC: 11694125.
DOI: 10.3324/haematol.2024.285219.
Das Barshan A, Matsumoto-Takahashi E
JMA J. 2024; 7(2):153-171.
PMID: 38721084
PMC: 11074501.
DOI: 10.31662/jmaj.2023-0171.
Zhu H, Lu X, Zhang X, Hua H, Zhang J, Miao Y
Ann Hematol. 2024; 103(12):5713-5727.
PMID: 38649594
DOI: 10.1007/s00277-024-05744-6.
Starkey T, Ionescu M, Tilby M, Little M, Burke E, Fittall M
Sci Rep. 2023; 13(1):11327.
PMID: 37491478
PMC: 10368624.
DOI: 10.1038/s41598-023-36990-9.
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Barnes E, Goodyear C, Willicombe M, Gaskell C, Siebert S, I de Silva T
Nat Med. 2023; 29(7):1760-1774.
PMID: 37414897
PMC: 10353927.
DOI: 10.1038/s41591-023-02414-4.
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.
Liatsou E, Ntanasis-Stathopoulos I, Lykos S, Ntanasis-Stathopoulos A, Gavriatopoulou M, Psaltopoulou T
Cancers (Basel). 2023; 15(8).
PMID: 37190194
PMC: 10136728.
DOI: 10.3390/cancers15082266.
Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders.
Magen H, Avigdor A, Nevo L, Fried S, Gibori A, Levin E
PLoS One. 2023; 18(5):e0284925.
PMID: 37126496
PMC: 10150979.
DOI: 10.1371/journal.pone.0284925.
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Ishio T, Tsukamoto S, Yokoyama E, Izumiyama K, Saito M, Muraki H
Ann Hematol. 2023; 102(6):1421-1431.
PMID: 37041299
PMC: 10089694.
DOI: 10.1007/s00277-023-05204-7.
Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia.
Engelmann R, Jaekel N, Jotschke S, Ludwig-Kraus B, Kraus F, Kumari N
Blood Adv. 2023; 7(14):3403-3415.
PMID: 36947191
PMC: 10065874.
DOI: 10.1182/bloodadvances.2022009054.
Effectiveness and Safety of COVID-19 Vaccination in Patients with Malignant Disease.
Zhao L, Fu L, He Y, Li H, Song Y, Liu S
Vaccines (Basel). 2023; 11(2).
PMID: 36851363
PMC: 9962104.
DOI: 10.3390/vaccines11020486.
Immune Response to COVID-19 Vaccination in Hematologic Malignancies: A Mini-Review.
Keshavarz S, Keshavarz S, Ziamajidi N, Daei S
Chonnam Med J. 2023; 59(1):24-30.
PMID: 36794237
PMC: 9900228.
DOI: 10.4068/cmj.2023.59.1.24.
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.
Uaprasert N, Pitakkitnukun P, Tangcheewinsirikul N, Chiasakul T, Rojnuckarin P
Blood Cancer J. 2022; 12(12):173.
PMID: 36550105
PMC: 9780106.
DOI: 10.1038/s41408-022-00776-5.
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.
Lee L, Tilby M, Starkey T, Ionescu M, Burnett A, Hattersley R
JAMA Oncol. 2022; 9(2):188-196.
PMID: 36547970
PMC: 9936347.
DOI: 10.1001/jamaoncol.2022.5974.
B-cell malignancies and COVID-19: a narrative review.
Luque-Paz D, Sesques P, Wallet F, Bachy E, Ader F
Clin Microbiol Infect. 2022; 29(3):332-337.
PMID: 36336236
PMC: 9633106.
DOI: 10.1016/j.cmi.2022.10.030.
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study.
Lee L, Ionescu M, Starkey T, Little M, Tilby M, Tripathy A
Eur J Cancer. 2022; 175:1-10.
PMID: 36084618
PMC: 9276646.
DOI: 10.1016/j.ejca.2022.06.038.
Immunogenicity of SARS-CoV-2 vaccines in patients with cancer.
Kakkassery H, Carpenter E, Patten P, Irshad S
Trends Mol Med. 2022; 28(12):1082-1099.
PMID: 35999131
PMC: 9345889.
DOI: 10.1016/j.molmed.2022.07.006.
Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences.
Kaminska D, Deborska-Materkowska D, Koscielska-Kasprzak K, Mazanowska O, Remiorz A, Poznanski P
Vaccines (Basel). 2022; 10(7).
PMID: 35891232
PMC: 9322013.
DOI: 10.3390/vaccines10071068.
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M, Azizi S, Abbasi Varaki F, Nejadghaderi S, Bashash D
Int Immunopharmacol. 2022; 110:109046.
PMID: 35843148
PMC: 9273573.
DOI: 10.1016/j.intimp.2022.109046.
Seroprevalence study prior and post vaccination in cancer patients in principality of Andorra (COVONCO study).
Royo-Cebrecos C, Robert-Montaner I, Vilanova D, Bailles E, Serrano-Pons J, Valero O
J Cancer Res Clin Oncol. 2022; 149(7):2883-2892.
PMID: 35809113
PMC: 10064610.
DOI: 10.1007/s00432-022-04141-8.
